Generic Industry Likely To See Increasing Geographic Diversification - Barr
This article was originally published in PharmAsia News
The generic drug industry has myriad reasons to expand into non-U.S. markets and will continue to do so, according to Barr CEO Bruce Downey
You may also be interested in...
Generic manufacturers may not want substitutability for follow-on biologics, Barr CEO Bruce Downey said Sept. 19 at the Generic Pharmaceutical Association Annual Policy Conference in Washington, D.C
The deep discounts seen with some recent high profile generic launches are not reflective of an eroding generic pricing environment, Teva maintains
Barr is highlighting its complementary product portfolio and business model in its efforts to ward off competition from Actavis to acquire Pliva